title: Endothelial venodilator response in carriers of genetic polymorphisms involved in NO synthesis and degradation.
abstract: OBJECTIVE
  Polymorphisms of the NOSIII gene and of the CYBA gene have been associated with a number of pathological conditions such as arterial hypertension, coronary artery disease, and myocardial infarction. Because endothelium-dependent vasodilation is impaired in these disorders, we hypothesized that polymorphisms of NOSIII or CYBA might modulate endothelial function of venous capacitance vessels already before cardiovascular disease becomes overt.
  
  
  METHODS
  Endothelium-dependent and -independent venodilation was assessed by measuring local vascular responses to bradykinin and sodium nitroprusside in the dorsal hand vein after preconstriction with phenylephrine in 72 healthy male Caucasians after careful exclusion of cardiovascular risk factors. Genotyping was performed for polymorphisms of the NOSIII gene (T-786C, G894T, (CA)(n)) and the CYBA gene (C242T).
  
  
  RESULTS
  Genotype distribution for each polymorphism followed the Hardy-Weinberg equilibrium. In all studied single nucleotide polymorphisms no significant difference between the respective genotypes and the venodilator response to either sodium nitroprusside or bradykinin was observed, and the number of CA repeat copies was not related to the venodilator response to bradykinin. Mean venodilation induced by bradykinin 50 ng min(-1) (+/-SEM) for homozygote carriers of the single nucleotide polymorphisms was 48.9 +/- 8.5% venodilation (G894T; wild type: 49.8 +/- 6.9), 50.3 +/- 11.0% venodilation (T-786C; wild type: 42.6 +/- 5.2), and 30.4 +/- 9.1% venodilation (C242T; wild type: 49.2 +/- 6.0), respectively.
  
  
  CONCLUSIONS
  This study suggests that the studied polymorphisms of NOSIII and CYBA do not significantly modulate endothelium-dependent venodilation in individuals without vascular risk factors.
authors.affiliation: Department of Internal Medicine VI, Clinical Pharmacology and Pharmacoepidemiology, University of Heidelberg, D-69120 Heidelberg, Germany.
authors.forename: Ruth
authors.initials: R
authors.lastname: Fricker
authors.forename: Christiane
authors.initials: C
authors.lastname: Hesse
authors.forename: Johanna
authors.initials: J
authors.lastname: Weiss
authors.forename: Yorki
authors.initials: Y
authors.lastname: Tayrouz
authors.forename: Michael M
authors.initials: MM
authors.lastname: Hoffmann
authors.forename: Kristina
authors.initials: K
authors.lastname: Unnebrink
authors.forename: Ulrich
authors.initials: U
authors.lastname: Mansmann
authors.forename: Walter E
authors.initials: WE
authors.lastname: Haefeli
mesh_terms: D001920:Bradykinin / Q000494:pharmacology; D002784:Cholesterol / Q000097:blood; D004730:Endothelium, Vascular / Q000378:metabolism; D005838:Genotype; D006579:Heterozygote; D006801:Humans; D008297:Male; D026901:Membrane Transport Proteins / Q000235:genetics*; D009252:NADPH Dehydrogenase / Q000235:genetics*; D019255:NADPH Oxidases; D009569:Nitric Oxide / Q000378:metabolism*; D019001:Nitric Oxide Synthase / Q000235:genetics*; D052250:Nitric Oxide Synthase Type III; D010750:Phosphoproteins / Q000235:genetics*; D016133:Polymerase Chain Reaction / Q000379:methods; D011110:Polymorphism, Genetic / Q000235:genetics*; D011446:Prospective Studies; D014664:Vasodilation / Q000235:genetics*
chemical_list: D026901:Membrane Transport Proteins; D010750:Phosphoproteins; D009569:Nitric Oxide; D002784:Cholesterol; C496314:NOS3 protein, human; D019001:Nitric Oxide Synthase; D052250:Nitric Oxide Synthase Type III; D019255:NADPH Oxidases; C086986:CYBA protein, human; D009252:NADPH Dehydrogenase; D001920:Bradykinin